Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study

OBJECTIVE: To assess the safety of rapidly dissolving buprenorphine/naloxone sublingual tablets (BNX-RDT) in opioid-dependent patients. METHODS: This open-label, 24-week extension study enrolled patients who completed primary trials of BNX-RDT. Daily tablet doses ranged from 5.7 to 17.1 mg. The prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman, Kent, Peyton, Marvin L., Sumner, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457835/
https://www.ncbi.nlm.nih.gov/pubmed/28353467
http://dx.doi.org/10.1097/ADM.0000000000000301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457835/
https://www.ncbi.nlm.nih.gov/pubmed/28353467
http://dx.doi.org/10.1097/ADM.0000000000000301

Ejemplares similares